InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the complete record of transactions filed by Hollander David, Directeur de la R&D. Officer active across 3 companies, notably Aerie Pharmaceuticals INC. Cumulatively, 5 reports have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €15k. Activity tracked since 11 November 2021. The latest transaction was filed on 1 September 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 条申报中的 5 条
David Hollander is the Chief R&D Officer at Aerie Pharmaceuticals Inc. He oversees the research and development activities of the company, which specializes in the pharmaceutical sector. His role is essential for innovation and the development of new products at Aerie.